Home/About CarePulse
40+ Years of Medical Leadership

Compassionate Medicine. Advanced Clinical Discovery.

CarePulse Health System is dedicated to delivering state-of-the-art medical therapies, innovative clinical research, and respectful, personalized care for every patient who walks through our doors.

480
Licensed Inpatient Beds

Private recovery suites with HEPA filtration

1.2M+
Patient Visits Annually

Across emergency, inpatient & outpatient

4th
Magnet Recognition

Awarded to top 2% of nursing hospitals

45+
Active Clinical Trials

Accelerating life-saving therapeutics

Our Mission

To preserve health, alleviate suffering, and provide empathetic, high-precision healthcare to all members of our community, regardless of circumstance or socioeconomic status.

Our Vision

To be the regional vanguard of intelligent digital healthcare—where clinical mastery and artificial intelligence merge to deliver predictive, preventative, and personalized cures.

Our Values

Patient First Always • Uncompromised Scientific Rigor • Empathy & Active Listening • Transparent Ethical Governance • Inclusivity and Community Advocacy.

Executive & Clinical Leadership

Physician Leaders Guiding Exceptional Care

Our executive committee brings together decades of surgical expertise, medical education, and hospital administration.

Dr. Evelyn Vance, MD, FACC

Dr. Evelyn Vance, MD, FACC

Chief Medical Officer & Chair of Cardiovascular Medicine

Johns Hopkins MD, Harvard Fellowship, Board Certified in Cardiology

Dr. Vance oversees hospital-wide clinical quality, robotic cardiovascular surgery initiatives, and patient safety protocols across all inpatient pavilions.

Dr. Marcus Chen, MD, PhD

Dr. Marcus Chen, MD, PhD

Director of Neurosciences Institute & Clinical Research

Harvard Medical School MD/PhD, Mass General Residency

Leading CarePulse's designated Comprehensive Stroke Center and spearheading clinical genomics trials in cerebrovascular perfusion.

Patricia Thornton, MSN, RN, NEA-BC

Patricia Thornton, MSN, RN, NEA-BC

Chief Nursing Officer & VP of Patient Experience

Yale School of Nursing MSN, 24 years acute care leadership

Championing patient-centered nursing care, resulting in CarePulse achieving its 4th consecutive ANCC Magnet Recognition designation.

Dr. Jonathan Hayes, MD

Dr. Jonathan Hayes, MD

Director of Oncology & Precision Therapeutics

Stanford University School of Medicine, NCI Research Fellow

Directing individualized immunotherapy protocols, cellular CAR-T therapies, and patient palliative care integration.

Four Decades of Healthcare Innovation

Key milestones that shaped CarePulse into a regional healthcare beacon.

1984

Foundation

Established as a regional 120-bed charitable hospital dedicated to cardiovascular health and trauma support.

1998

Level 1 Trauma Designation

Designated as the region's foremost Level 1 Adult & Pediatric Trauma Center with round-the-clock surgical response.

2012

Comprehensive Cancer Pavilion

Opened the 8-story Hayes Cancer Institute offering integrated radiation oncology, infusion, and genomic testing.

2024

AI Clinical Suite & Telehealth

Pioneered automated diagnostic triage, real-time vital telemetry, and encrypted digital patient health records.

Quality & Safety Benchmark

Uncompromising Standards in Patient Protection

CarePulse maintains continuous verification from international accreditation bodies, ensuring infection control, surgical safety, and privacy that exceed national baselines.

The Joint Commission Gold Seal of Approval

Comprehensive hospital and laboratory accreditation affirming adherence to highest clinical safety guidelines.

ANCC Magnet Recognition

Recognized for premier nursing leadership, compassionate bedside patient ratios, and professional practice.

HIPAA Security & Privacy Certified

Military-grade 256-bit encryption protecting patient health records, telehealth streams, and diagnostic messaging.

Academic Research & Clinical Trials

Accelerating bench-to-bedside discoveries

Through formal academic affiliations, CarePulse physicians conduct Phase I–IV clinical investigations in novel cardioprotective compounds, stroke neuroprotection, and targeted immunotherapies. Patients receive early access to breakthrough therapies under supervised protocols.